Natural health product labels: Is more information always better?

Patient Education and Counseling

Volumn 68, Issue 2, 2007, Pages 193-199

  Boon, Heather S ^a   Kachan, Natasha ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Consumer perceptions; Natural health products (NHPs); NHP regulations; Over the counter (OTC); Qualitative research; Risk

Indexed keywords

NATURAL PRODUCT; NON PRESCRIPTION DRUG; PASSIFLORA PERFORATUM EXTRACT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANADA; CLINICAL ARTICLE; CONSUMER; CONTENT ANALYSIS; DRUG CROSS REACTIVITY; FEMALE; HERBAL MEDICINE; HUMAN; MALE; PACKAGING; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITY CONTROL; RISK ASSESSMENT; STANDARDIZATION;

ADULT; AGED; ATTITUDE TO HEALTH; COMPLEMENTARY THERAPIES; DRUG INFORMATION SERVICES; FEMALE; FOCUS GROUPS; FRUSTRATION; GOVERNMENT REGULATION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; NURSING METHODOLOGY RESEARCH; ONTARIO; PATIENT EDUCATION AS TOPIC; PRODUCT LABELING; QUALITATIVE RESEARCH; QUESTIONNAIRES; RISK FACTORS; SAFETY; TRUST;

EID: 34548476771     PISSN: 07383991     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pec.2007.06.005     Document Type: Article

References (47)

1. Traulsen J., and Bissell P. The risk society. In: Bissell P., and Traulsen J. (Eds). Sociology and pharmacy practice (2005), Pharmaceutical Press, Cornwall 251-259
2. Her Majesty the Queen in Right of Canada. Natural Health Products Regulations. Canada Gazette Part II. June 18, 2003;137.
3. Zaffani S., Cuzzolin L., and Benoni G. Herbal products: behaviours and beliefs among Italian women. Pharmacoepidem Dr S 15 (2006) 354-359
4. Krewski D., Lemyre L., Turner M., Lee J., Dallaire C., Bouchard L., Brand K., and Mercier P. Public perception of population health risks in Canada: health hazards and sources of information. Hum Ecol Risk Assess 12 (2006) 626-644
5. Boon H., Brown J.B., Gavin A., Kennard M.A., and Stewart M. Breast cancer survivors' perceptions of complementary/alternative medicine (CAM): making the decision to use or not to use. Qual Health Care 9 (1999) 639-653
6. Boon H., Brown J.B., Gavin A., and Westlake K. Men with prostate cancer: making decisions about complementary/alternative medicine. Med Decis Making 3 (2003) 471-479
7. Barnes J., Mills S., Abbot N., Willoughby M., and Ernst E. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. Brit J Clin Pharmaco 45 (1998) 496-500
8. Nabors L., Lehmkuhl H., Parkins I., and Drury A. Reading about over-thecounter medications. Issues Compr Pediatr Nurs 27 (2004) 297-305
9. Hughes L., Whittlesea C., and Luscombe D. Patients' knowledge and perceptions of the side effects of OTC medication. J Clin Pharm Ther 27 (2002) 243-
10. Roby C.A., Anderson G.D., Kantor E., Dryer D.A., and Burstein A.H. St. John's wort: effect on CYP3A4 activity. Clin Pharmaco Ther 67 (2000) 451-457
11. Ernst E. Second thoughts about the safety of St. John's wort. Lancet 1999;355:134-38.
12. Health Canada Advisory. Potentially harmful drug interaction with St. John's wort and prescription drugs; April 7, 2000. Report No. 2000-36.
13. Henney J.E. Risk of drug interactions with St. John's wort. J Am Med Assoc 283 (2000) 1679
14. CP H, K M, K B, RB F. Toxicity and drug interactions associated with herbal products: Ephedra and St. John's Wort. Medical Clinics of North America 2005;89:1225-57.
15. Teschke R., Gaus W., and Loew D. Kava extracts: safety and risks including rare hepatotoxicity. Phytomedicine 10 (2003) 440-446
16. Health Canada. Health Canada is advising consumers not to use any products containing kava [Advisory], Ottawa, available: www.hc-sc.gc.ca/english/protection/warnings/2002/2002_02e.html, Jan 16, 2002.
17. Stevinson C., Huntley A., and Ernst E. A systematic review of the safety of kava extract in the treatment of anxiety. Dr S 25 (2002) 251-261
18. Health Canada. Health Canada issues a stop-sale order for all products containing kava [Advisory], Ottawa, available at: www.hc-sc.gc.ca/english/protection/warnings/2002/2002_56e.html, August 21, 2002.
19. Blumenthal M. Kava safety questioned due to case reports of liver toxicity. HerbalGram 55 (2002) 26-32
20. Cavaliere C, Blumenthal M. UK Expert Committee Upholds Kava Ban. HerbalGram 2006;72:59.
21. Blumenthal M. FDA Announces Ban on Ephedra Supplements: Federal Move FollowsBans by California, Illinois and New York (Expanded Version). HerbalGram 2004;61:0.
22. EM B, JC S, UB. T. Safety assurances for dietary supplements: policy issues and new research paradigms. J Herb Pharmacother 2005;5:3-15.
23. Wilcox C., and Cryer B. Triadafilopoulos G. patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal anti-inflammatory drugs. J Rheumatol 32 (2005) 2218-2224
24. Wazaify M., Shields E., Hughes C., and McElnay J. Societal perspectives on over-the-counter (OTC) medicines. Fam Pract 22 (2005) 170-176
25. Moldrup C., Morgall J., and Almarsdottir A. Perceived risk of future drugs-Danish citizens delphi. Health Risk Soc 4 (2002) 5-17
26. Roumie C., and Griffin M. Over-the-counter analgesics in older adults: a call for improved labeling and consumer education. Drugs Aging 21 (2004) 485-498
27. Beck U. Risk society-towards a new modernity (1992), Sage, London
28. Giddens A. The consequences of modernity (1990), Polity Press, Cambridge
29. Giddens A. Modernity and self-identity. Self and society in the late modern age (1991), Stanford University Press, Cambridge
30. Boon H. Regulation of complementary/alternative medicine: a Canadian perspective. Complem Ther Med 10 (2002) 14-19
31. Boon H. Regulation of natural health products in Canada. Clin Res Regul Aff 20 (2003) 299-312
32. Natural Health Products Directorate. Site Licensing http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-site-exploit/index_e.html, accessed May 5, 2006.
33. Natural Health Products Directorate. Product Licensing, cited available from: http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/index_e.html, accessed May 5, 2006.
34. Volpe JC. Natural health products: a new vision. Report of the Standing Committee on Health, Ottawa, November, 1998.
35. Morgan D.L. Focus groups as qualitative research (1988), Sage, Newbury Park, CA
36. MacDougall C., and Fudge E. Planning and recruiting the sample for focus groups and in-depth interviews. Qual Health Res 11 (2001) 117-126
37. Creswell J.W. Qualitative inquiry and research design. Choosing among five traditions (1998), Sage Publications Inc., Thousand Oaks, CA
38. Qualitative Solutions Research Pvt. Ltd. QSR NVivo 2.1 for Windows. 5th ed. (2002), Qualitative Solutions & Research Pvt. Ltd., Melbourne, Australia
39. In: Denzin N.K., and Lincoln Y.S. (Eds). Handbook of qualitative research. 2nd ed. (2000), Sage, Thousand Oaks, CA
40. Berg B.L. Qualitative research methods for the social sciences. 2nd ed. (1995), Allyn and Bacon, Needham Heights, MA
41. Boyatzis R. Transforming qualitative information: thematic analysis and code development (1998), Thousand Oaks, CA, Sage
42. Wynne B. May the sheep safely graze? A reflexive view of the expert-lay knowledge divide. In: lash S., and Szerszinski B.B.W. (Eds). Risk, environment and modernity: towards a new ecology (1996), Sage, London
43. Williams S., and Clanan M. The 'limits' of medicalization? Modern medicine and the lay populace in late modernity. Soc Sci Med 42 (1996) 1609-1620
44. Thomspons M. Aesthetics of risk: culture or conflict?. In: Sching R., and Alens W. (Eds). Societal risk assessment: how safe is safe enough? (1980), Plenum, New York
45. Douglas M. Risk and blame. Essays in cultural theory (1992), Routledge, London
46. Douglas M. Risk acceptability according to the social sciences (1985), Russell Sage Foundation, New York
47. Kaufman. Recent patterns of medication use in the ambulatory adult population of the United States. The Slone Survey. J Am Med Assoc 2002;287:337-44.